179 related articles for article (PubMed ID: 32753678)
1. Development of an artificial antibody specific for HLA/peptide complex derived from cancer stem-like cell/cancer-initiating cell antigen DNAJB8.
Tadano H; Tsukahara T; Mizushima E; Akamatsu A; Watanabe K; Nojima I; Kubo T; Kanaseki T; Hirohashi Y; Sato N; Torigoe T
Br J Cancer; 2020 Oct; 123(9):1387-1394. PubMed ID: 32753678
[TBL] [Abstract][Full Text] [Related]
2. Development of CAR-T cells specifically targeting cancer stem cell antigen DNAJB8 against solid tumours.
Watanabe Y; Tsukahara T; Murata K; Hamada S; Kubo T; Kanaseki T; Hirohashi Y; Emori M; Teramoto A; Nakatsugawa M; Yamashita T; Torigoe T
Br J Cancer; 2023 Mar; 128(5):886-895. PubMed ID: 36526673
[TBL] [Abstract][Full Text] [Related]
3. Heat shock protein DNAJB8 is a novel target for immunotherapy of colon cancer-initiating cells.
Morita R; Nishizawa S; Torigoe T; Takahashi A; Tamura Y; Tsukahara T; Kanaseki T; Sokolovskaya A; Kochin V; Kondo T; Hashino S; Asaka M; Hara I; Hirohashi Y; Sato N
Cancer Sci; 2014 Apr; 105(4):389-95. PubMed ID: 24450541
[TBL] [Abstract][Full Text] [Related]
4. Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody.
Tsukahara T; Emori M; Murata K; Hirano T; Muroi N; Kyono M; Toji S; Watanabe K; Torigoe T; Kochin V; Asanuma H; Matsumiya H; Yamashita K; Himi T; Ichimiya S; Wada T; Yamashita T; Hasegawa T; Sato N
J Biol Chem; 2014 Aug; 289(32):22035-47. PubMed ID: 24962571
[TBL] [Abstract][Full Text] [Related]
5. Identification of antigenic peptides from novel renal cancer stem-like cell antigen, DNAJB8.
Nishizawa S; Hirohashi Y; Kusumoto H; Wakamiya T; Iguchi T; Yamashita S; Iba A; Kikkawa K; Kohjimoto Y; Torigoe T; Hara I
Biochem Biophys Res Commun; 2017 Dec; 494(3-4):693-699. PubMed ID: 29107688
[TBL] [Abstract][Full Text] [Related]
6. Cellular stress induces cancer stem-like cells through expression of DNAJB8 by activation of heat shock factor 1.
Kusumoto H; Hirohashi Y; Nishizawa S; Yamashita M; Yasuda K; Murai A; Takaya A; Mori T; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Kondo T; Sato N; Hara I; Torigoe T
Cancer Sci; 2018 Mar; 109(3):741-750. PubMed ID: 29316077
[TBL] [Abstract][Full Text] [Related]
7. HSP DNAJB8 controls tumor-initiating ability in renal cancer stem-like cells.
Nishizawa S; Hirohashi Y; Torigoe T; Takahashi A; Tamura Y; Mori T; Kanaseki T; Kamiguchi K; Asanuma H; Morita R; Sokolovskaya A; Matsuzaki J; Yamada R; Fujii R; Kampinga HH; Kondo T; Hasegawa T; Hara I; Sato N
Cancer Res; 2012 Jun; 72(11):2844-54. PubMed ID: 22552285
[TBL] [Abstract][Full Text] [Related]
8. Development of a T-cell receptor multimer with high avidity for detecting a naturally presented tumor-associated antigen on osteosarcoma cells.
Watanabe K; Tsukahara T; Toji S; Saitoh S; Hirohashi Y; Nakatsugawa M; Kubo T; Kanaseki T; Kameshima H; Terui T; Sato N; Torigoe T
Cancer Sci; 2019 Jan; 110(1):40-51. PubMed ID: 30375705
[TBL] [Abstract][Full Text] [Related]
9. Dnajb8, a Member of the Heat Shock Protein 40 Family Has a Role in the Tumor Initiation and Resistance to Docetaxel but Is Dispensable for Stress Response.
Yamashita M; Hirohashi Y; Torigoe T; Kusumoto H; Murai A; Imagawa T; Sato N
PLoS One; 2016; 11(1):e0146501. PubMed ID: 26751205
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24
Minami T; Matsumura N; Sugimoto K; Shimizu N; De Velasco M; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
Int Immunopharmacol; 2017 Mar; 44():197-202. PubMed ID: 28110220
[TBL] [Abstract][Full Text] [Related]
11. Identification of Programmed Death Ligand 1-derived Peptides Capable of Inducing Cancer-reactive Cytotoxic T Lymphocytes From HLA-A24+ Patients With Renal Cell Carcinoma.
Minami T; Minami T; Shimizu N; Yamamoto Y; De Velasco M; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
J Immunother; 2015 Sep; 38(7):285-91. PubMed ID: 26261892
[TBL] [Abstract][Full Text] [Related]
12. Identification of erythropoietin receptor-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from HLA-A24(+) patients with renal cell carcinoma.
Minami T; Minami T; Shimizu N; Yamamoto Y; De Velasco M; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
Int Immunopharmacol; 2014 May; 20(1):59-65. PubMed ID: 24583149
[TBL] [Abstract][Full Text] [Related]
13. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy.
Suda T; Tsunoda T; Daigo Y; Nakamura Y; Tahara H
Cancer Sci; 2007 Nov; 98(11):1803-8. PubMed ID: 17784873
[TBL] [Abstract][Full Text] [Related]
14. Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.
Zhao Q; Ahmed M; Tassev DV; Hasan A; Kuo TY; Guo HF; O'Reilly RJ; Cheung NK
Leukemia; 2015 Nov; 29(11):2238-47. PubMed ID: 25987253
[TBL] [Abstract][Full Text] [Related]
15. HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma.
Komohara Y; Harada M; Ishihara Y; Suekane S; Noguchi M; Yamada A; Matsuoka K; Itoh K
Oncol Rep; 2007 Dec; 18(6):1463-8. PubMed ID: 17982631
[TBL] [Abstract][Full Text] [Related]
16. Identification of target antigens in specific immunotherapy for renal cell carcinoma.
Komohara Y; Harada M; Arima Y; Suekane S; Noguchi M; Yamada A; Itoh K; Matsuoka K
J Urol; 2007 Mar; 177(3):1157-62. PubMed ID: 17296437
[TBL] [Abstract][Full Text] [Related]
17. Identification of an HLA-A*24:02-restricted α-fetoprotein signal peptide-derived antigen and its specific T-cell receptor for T-cell immunotherapy.
Li Z; Gong H; Liu Q; Wu W; Cheng J; Mei Y; Chen Y; Zheng H; Yu X; Zhong S; Li Y
Immunology; 2020 Apr; 159(4):384-392. PubMed ID: 31849039
[TBL] [Abstract][Full Text] [Related]
18. Regulatory inter-domain interactions influence Hsp70 recruitment to the DnaJB8 chaperone.
Ryder BD; Matlahov I; Bali S; Vaquer-Alicea J; van der Wel PCA; Joachimiak LA
Nat Commun; 2021 Feb; 12(1):946. PubMed ID: 33574241
[TBL] [Abstract][Full Text] [Related]
19. Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response.
Yamaguchi H; Tanaka F; Ohta M; Inoue H; Mori M
Clin Cancer Res; 2004 Feb; 10(3):890-6. PubMed ID: 14871964
[TBL] [Abstract][Full Text] [Related]
20. A newly identified MAGE-3-derived, HLA-A24-restricted peptide is naturally processed and presented as a CTL epitope on MAGE-3-expressing gastrointestinal cancer cells.
Miyagawa N; Kono K; Mimura K; Omata H; Sugai H; Fujii H
Oncology; 2006; 70(1):54-62. PubMed ID: 16446550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
